simvastatin + placebo
Pre-clinicalCompleted 0 watching 0 views this week๐ค Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carotid Artery Disease
Conditions
Carotid Artery Disease
Trial Timeline
Sep 1, 2002 โ Mar 1, 2006
NCT ID
NCT00587717About simvastatin + placebo
simvastatin + placebo is a pre-clinical stage product being developed by Merck for Carotid Artery Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00587717. Target conditions include Carotid Artery Disease.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00935259 | Phase 1 | Completed |
| NCT00321802 | Phase 2 | Completed |
| NCT00486044 | Phase 2 | Completed |
| NCT00588471 | Pre-clinical | Terminated |
| NCT00704314 | Pre-clinical | Completed |
| NCT00587717 | Pre-clinical | Completed |
Competing Products
9 competing products in Carotid Artery Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Abciximab | Eli Lilly | Phase 1/2 | 41 |
| Rosuvastatin | AstraZeneca | Phase 3 | 77 |
| Rosuvastatin (5mg๏ผ10mg๏ผ20mg) + Rosuvastatin 5mg | AstraZeneca | Approved | 85 |
| Niacin/simvastatin compared to simvastatin alone at 2 doses | Merck | Approved | 85 |
| Atorvastatin/niacin extended-release + Atorvastatin + Simvastatin + Simvastatin | Merck | Phase 2 | 52 |
| Evolocumab | Amgen | Approved | 84 |
| Atorvastatin - Cholestyramine - Sitosterol | Pfizer | Pre-clinical | 22 |
| Rimonabant + Placebo (for Rimonabant) | Sanofi | Phase 3 | 76 |
| Gadobutrol (Gadovist, BAY86-4875) | Bayer | Phase 3 | 74 |